Chris O’Brien

No ORCID on file · 5 papers in corpus · active 2009-2015

Study types

  • article 5

Condition tags

  • endometriosis 5
  • dysmenorrhea 1
  • chronic_pelvic_pain 1
  • dyspareunia 1
article 2015
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist: Results from a Phase 2, Randomized Controlled Study
·doi:10.5301/je.5000211

Purpose Elagolix is a novel, oral GnRH antagonist that dose-dependently suppresses estradiol levels. This study evaluated safety and efficacy of elagolix vs. leuprorelin acetate (LA) and placebo in women with endometriosis-associated pain. …

article 2014
Elagolix, an Oral GnRH Antagonist, Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis: Effects on Bone Mineral Density
Reproductive sciences (Thousand Oaks, Calif.) ·doi:10.1177/1933719114549848

This randomized double-blind study, with 24-week treatment and 24-week posttreatment periods, evaluated the effects of elagolix (150 mg every day, 75 mg twice a day) versus subcutaneous depot medroxyprogesterone acetate (DMPA-SC) on bone mi…

article 2013
Elagolix, an Oral GnRH Antagonist for Endometriosis-Associated Pain: A Randomized Controlled Study
Journal of endometriosis and pelvic pain disorders ·doi:10.5301/je.5000157

OBJECTIVE: The aim of this study was to estimate the efficacy of elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist, for the treatment of endometriosis-associated pelvic pain. METHODS: This was a phase II, randomized, placeb…

article 2011
A novel oral GnRH antagonist, elagolix, is effective for reducing endometriosis-associated pelvic pain: results of a 24-week randomized study
·doi:10.1016/j.fertnstert.2011.07.171
article 2009
Petal study: safety, tolerability and effectiveness of elagolix, an oral GnRH antagonist for endometriosis
·doi:10.1016/j.fertnstert.2009.07.1100